ATTD 2026 Resource Hub  – 

Welcome to our resource hub for ATTD 2026! This is a one-stop-shop for all your ATTD 2026 needs. We will be updating the resource hub daily, so check back in for the latest on this fantastic meeting.

Day-of Conference Reports

Diabetes Technology Highlights

  1. Opening Lecture on human-AI collaboration in diabetes: Prof. Boris Kovatchev on developing AI digital twins
  2. Insulet: Drs. Trang Ly and Martin de Bock on “Helping diabetes disappear”: Fully closed-loop AID for T2D and beyond
  3. Abbott: Experts highlight continuous ketone monitoring and its applications to dual glucose-ketone sensing (DGK) for the prevention of DKA
  4. Roche: Profs. Bogdan Timar and Guido Freckmann on moving from trend-following to proactive intervention with CGM
  5. Expanding the role of CGM in diabetes detection and early diabetes management
  6. Tandem: Features, early user data, and glycemic strategies with Tandem Mobi
  7. Prof. Emma Wilmot addresses evidence and access for CGM in T2D
  8. Inpatient diabetes management: Emerging CGM evidence highlights improvements in glycemic outcomes in the hospital
  9. FreeDM2 trial: FreeStyle Libre 3 improves A1c and TIR compared to BGM in adults with T2D on basal insulin and SGLT-2 inhibitors or incretins
  10. Using AID to overcome clinical inertia in basal insulin dosing for T2D
  11. Dr. Viral Shah on CGM for prediabetes: Staging, diagnosis, and potential therapeutic options
  12. Fully closed-loop AID: Dr. Rayhan Lal discusses future challenges and considerations
  13. CGM use in people without diabetes: New metrics for phenotyping, Time in Tight Range, and foundation models for glucose
  14. Real-world performance of the Instinct sensor with the MiniMed 780G AID system
  15. From hybrid to fully closed-loop: Dr. Marc Breton discusses UVA’s AIDANET AI-driven AID system and early trial results
  16. dQ&A presents data on DKA awareness and ketone testing behavior of adults with T1D
  17. Dexcom unveils Smart Basal dosing, extended high glucose alerts, and a new sensor patch in dynamic symposium
  18. Toward hands-off diabetes care: MiniMed unveils the Vivera fully closed-loop algorithm
  19. Debate: Should A1c or CGM be the gold standard for glycemic management?
  20. mylife Diabetes Care: Evidence and clinical pearls for personalization AID with CamAPS FX
  21. CGM metrics as predictors of vascular risk: Insights from Virtual DCCT and real‑world evidence
  22. Dr. Ahmad Haider takes a first pass at recommendations for continuous ketone level targets for people with T1D on SGLT-2 inhibitors
  23. A preview of continuous ketone monitoring data from Abbott; Drs. Ketan Dhatariya and Rich Bergenstal highlight much to be learned
  24. From prediabetes to basal insulin: Early CGM use to transform T2D care
  25. Integrating wearable technology into adult diabetes care
  26. An opportunity for a “generational leap”: Use of ultra-rapid acting insulin in AID systems
  27. Interoception and education: Prof. Stephanie Amiel on the CLEAR trial and HARPdoc for improving hypoglycemia awareness in T1D
  28. Omnipod 5 in the real world: Evidence in infants and toddlers, those with very low insulin requirements, and those using optimal settings
  29. Sequel MedTech shares real-world data from the first twiist users (n=274), with mean TIR of 77% and TBR of 2.9%
  30. MiniMed presents three studies comparing Simplera Sync and Instinct, studying low glucose alerts, and exploring missed meal boluses
  31. Results from Italian study of adolescents with T1D switching between Guardian 4 and Simplera Sync sensors
  32. New Eversense 365 CGM real-world data (n=5,000+) shows up to 72% TIR; preliminary data from twiist AID integration shows 77% TIR
  33. CGM use is not effective for healthy lifestyle modification in people without diabetes
  34. Diabetic ketoacidosis in T1D and T2D: Epidemiology, provider perspectives, and the promising role of technology
  35. Dr. David Klonoff on the glycemic risk index and its clinical and research benefits
  36. MiniMed symposium spotlights simplified onboarding for 780G, future innovation pipeline, and MiniMed Go
  37. Clinical implications of extended-wear infusion sites in insulin pump therapy
  38. Biolinq’s intradermal glucose monitor: Feasibility data supports longer wear time
  39. Accuracy of a novel, real-time CGM in adults with diabetes: A preliminary analysis
  40. India D-Tech session takes on diabetes care gaps with clinical decision support and practical CGM use
  41. Use of CGM in gestational diabetes; CGM metrics show differences in GDM status well before OGTT
  42. Glycemic outcomes associated with switching from intermittently-scanned to real-time CGM in people with T2D on insulin
  43. dQ&A study examines the impact of AID systems on diabetes burden and user satisfaction
  44. First phase 1 data for PharmaSens’ combined insulin patch pump and CGM; second clinical trial planned for 2Q26
  45. The future of smart pens: Market growth, real‑world uptake, and pediatric use
  46. *NEW* Feasibility of decentralized clinical trials in diabetes management studies
  47. *NEW* Dr. Jennifer Sherr on strategies to optimize outcomes with AID
  48. *NEW* Large real‑world analysis finds significant reductions in MACE and mortality with CGM use in T1D

Diabetes Therapy Highlights

  1. Lilly: Profs. Chantal Mathieu and Harpreet Bajaj on the potential for once-weekly insulins, including in combination with GLP-1 RAs, metformin, and AID system
  2. Vertex: Symposium reflects on the T1D landscape and highlights the next chapter with islet cell therapy
  3. Dr. Anastasia Albanese-O’Neill on building a global consensus for early-stage T1D screening and monitoring at the general population level
  4. EDENT1FI screens over 100,000 children in Europe for early stage T1D
  5. Sanofi’s symposium highlights the future of T1D screening and disease-modifying therapies
  6. SURPASS-EARLY: Early initiation of tirzepatide for T2D improves glycemic and cardiovascular health
  7. Dr. Jeremy Pettus introduces a novel gene therapy for T1D, KRIYA-839, which will enter the first-in-human phase 1/2 trial in 2026
  8. Post-hoc analysis of the QWINT program finds comparable hypoglycemia duration between once-weekly efsitora alfa and daily basal insulin
  9. Dr. Viswanathan Mohan on the distinction between IFG and IGT in diabetes prevention
  10. Adjust T1D study of GLP-1 RA use in adults with T1D and obesity shows significant reductions in cardiovascular outcomes and disease risk
  11. Real-world evidence of reclassification to T1D following misdiagnosis
  12. Dr. Satish Garg on the adjunctive use of incretins in T1D and obesity: Recommendations from an upcoming consensus report
  13. Interim results for Diamyd’s phase 3 DIAGNODE-3 results for retogatein in stage 3 T1D expected by end of month
  14. Clinical pearls on once-weekly insulin use in insulin-naïve and insulin-experienced people with T2D
  15. T1D screening and monitoring: IDF Europe’s international consensus on for early-stage T1D now published
  16. Lilly symposium: SURPASS‑EARLY trial underscores the potential to alter T2D progression with early tirzepatide treatment
  17. Eight years of normoglycemia in preclinical T1D models of KRIYA-839; one administration designed to last a patient’s lifetime
  18. Immediate, intensive glycemic management for T2D: An argument for early insulin initiation
  19. Dr. Jay Skyler and his “mission to eradicate T1D”
  20. Saliva-based screening: T1D Scout’s program to expand large-scale screening by identifying high-risk populations
  21. Obesity in T1D: Etiology and GLP-1 RAs as a promising therapy

Big Picture Highlights

  1. Opening Ceremony highlights ATTD’s global reach
  2. ATTD 2026 exhibit hall brings together 80+ companies highlighting the latest in diabetes technologies and therapies
  3. Breakthrough T1D to train interventional diabetologists and endocrinologists through US certificate program and joint course with ATTD
  4. Delaying the onset of T1D: Screening and treatment options
  5. Bridging the gap between population screening and initiation of immunotherapy
  6. Exercise and T1D: Physiological differences, clinical trials, real-world evidence, and continuous lactate monitoring
  7. IDF Europe symposium focuses on diabetes detection, treatments, and cures
  8. Beyond glycemia: Addressing overweight and obesity in T1D
  9. Early-onset T2D in pregnancy: Prof. Helen Murphy highlights rising prevalence and urgent need for stronger preconception care
  10. C-peptide as a marker for functional beta cell mass: Pushing the momentum for disease-modifying T1D treatment
  11. Cardiovascular disease in T1D: Pathophysiology, pharmacotherapy, and exercise
  12. Prof. Chantal Mathieu receives ATTD Breakthrough Award during closing ceremony
ATTD 2026 Resource Hub -
Top